Perceptive Advisors’s Albireo Pharma Inc ALBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-1,757,160
Closed -$38M 113
2022
Q4
$38M Sell
1,757,160
-602,979
-26% -$12.7M 1.07% 27
2022
Q3
$45.7M Hold
2,360,139
1.33% 23
2022
Q2
$46.9M Hold
2,360,139
1.47% 16
2022
Q1
$70.4M Hold
2,360,139
1.41% 20
2021
Q4
$55M Hold
2,360,139
0.85% 31
2021
Q3
$73.6M Hold
2,360,139
1.07% 26
2021
Q2
$83M Hold
2,360,139
1.08% 25
2021
Q1
$83.2M Hold
2,360,139
1.05% 25
2020
Q4
$88.5M Hold
2,360,139
0.95% 29
2020
Q3
$78.8M Buy
2,360,139
+400,000
+20% +$11.7M 1.15% 22
2020
Q2
$51.9M Hold
1,960,139
0.84% 30
2020
Q1
$31.9M Buy
1,960,139
+255,809
+15% +$5.62M 0.83% 28
2019
Q4
$43.3M Hold
1,704,330
0.86% 28
2019
Q3
$34.1M Hold
1,704,330
0.92% 29
2019
Q2
$54.9M Hold
1,704,330
1.26% 18
2019
Q1
$54.9M Hold
1,704,330
1.55% 20
2018
Q4
$39.5M Hold
1,704,330
1.5% 22
2018
Q3
$56.2M Hold
1,704,330
1.5% 22
2018
Q2
$60.5M Hold
1,704,330
1.59% 16
2018
Q1
$55.5M Buy
1,704,330
+384,330
+29% +$12.9M 1.55% 19
2017
Q4
$33.8M Buy
1,320,000
+475,000
+56% +$12M 1.12% 22
2017
Q3
$17.7M Hold
845,000
0.68% 35
2017
Q2
$17.4M Buy
+845,000
New +$17.3M 0.88% 33

Other funds holding ALBO

Perceptive Advisors's ALBO Position: Q1 2023 in Review

Perceptive Advisors sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 1,757,160 shares — an estimated $38M sold.

Perceptive Advisors first reported a position in ALBO in Q2 2017 and held it in 23 quarters. The position peaked at $88.5M in Q4 2020. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Perceptive Advisors reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Perceptive Advisors sold 1,757,160 Albireo Pharma Inc shares in Q1 2023, an estimated $38M.
  • Perceptive Advisors first reported a position in Albireo Pharma Inc in Q2 2017 and held it in 23 quarters.
  • Perceptive Advisors's Albireo Pharma Inc position peaked at $88.5M in Q4 2020.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Perceptive Advisors's 13F filing for Q1 2023, filed 15 May 2023.